CAREERS Careers Overview Life at Lupin Campus Connect Learning & Development Current Openings P.L.E.D.G.E.
CONTACT US Contact Us Global Offices Partner With Us Lupin for Suppliers GST Information


Lupin’s Europe business recorded a growth of 2% with sales of Rs.5,498 million during the year. As part of our strategic vision, we have a strong focus on building a Specialty products portfolio while continuing to grow our Generics business in the region. On the Generic side, we continue to build on a meaningful portfolio of niche products while extending and deepening the relationships with our strategic partners within Europe. Our Specialty play in the Neurology space for the European region, together with our strong pipeline in Complex Generics, Biosimilars and Inhalation will further enhance the value of our business.

We have filed three marketing authorization applications with the EU Authorities, having received two approvals (including NaMuscla) during FY2019. At present, the cumulative filings for Europe stand at 60 with 56 approvals to date.